Sunovion Pharmaceuticals Inc. has divulged new trace amine-associated receptor 1 (TAAR1; TAR1) agonists and/or 5-HT2A and/or 5-HT7 receptor antagonists reported to be useful for the treatment of bipolar and autism spectrum disorders, schizophrenia, substance abuse and dependence, Alzheimer's, Parkinson's and metabolic diseases.